Xiaoguang Cai

About Xiaoguang Cai

Xiaoguang is a counsel in our global transactions team.

He specialises in cross-border transactions with a focus on advising Chinese and multinational clients on their investments, including M&A and joint ventures, across a range of industries. Xiaoguang is qualified in Germany and based in Berlin, having previously worked in our Shanghai office.

Xiaoguang speaks German, English and Mandarin.

Recent work

• Advising ABB on the acquisition of the Chinese wiring accessories business of Siemens.
• Advising Fresenius on the divestiture of Eugin Group to KKR porfolio company IVI-RMA global and GED Capital.
• Advising Trilantic Europe on the acquisition of a majority staje in Aerocompact Group.
• Advising Springer Nature on the divestment of its business for mobility education and training solutions to Unigestion.
• Advising a Chinese consortium on the acquisition of a majority stake in a leading global manufacturer of high-precision technical equipment.
• Advising the shareholders of MYR GmbH, a German biotechnology company focusing on the development and ccommercialisation of therapeutics for the treatment of chronic hepatitis delta virus (HDV), on their sale of MYR GmbH for approx. € 1.5 billion to Gilead Sciences, Inc. 
• Advising leading academic publisher Springer Nature on the divestiture of its India-based publishing services business to a Partners Group portfolio company.
• Advising Springer Nature in connection with its investment in US tech company Research Square Platform, including the acquisition of a majority stake.
• Advising Saudi Basic Industries Corporation on establishing a joint venture with German SCHMID Group in the field of energy storage technology to construct one of the world’s largest utility-scale battery factories.
• Advising Mars, Inc. on the acquisition of foodspring, a Berlin based tech company in the targeted nutrition sector.
• Advising ChemChina Group on the material asset restructuring in connection with the reverse IPO of its German subsidiary KraussMaffei Group at the Shanghai Stock Exchange.
• Advising Advent International on the acquisition of Bonitas Group, one of the largest private care providers in Germany.
• Advising Advent International on the acquisition of Zentiva, Sanofi Group’s European generics business, for approx. € 1.9 billion.
• Advising Anheuser-Busch InBev on the carve-out and divestment of its German beer brands Hasseröder and Diebels.
• Advising KPMG International in connection with the set-up of its global services center in Berlin. 
• Advising CREAT Group on the contemplated material asset restructuring in connection with its German listed subsidiary Biotest AG.
• Advising New-York-based venture capital firm New Science Venture on its investment in German technology company zeotap GmbH.
• Advising Clayton, Dubilier & Rice LLC on the acquisition of German Kalle Group from Silverfleet Capital.
• Advising Staidson (Beijing) Biopharmaceuticals on its investment in German biopharma company InflaRx GmbH.
• Advising a Chinese consortium led by Elec-Tech International on its proposed acquisition of Osram’s consumer lighting division.
• Advising Shanghai Feilo Acoustics Co., Ltd. on the acquisition of Havells Sylvania.